top of page

Publications

A scalable serology solution for profiling humoral immune responses to SARS-CoV-2 infection and vaccination

Colwill K, Galipeau Y, Stuible M, Gervais C, Arnold C, Rathod B, et al

Comparative performance data for multiplex SARS-CoV-2 serological assays from a large panel of dried blood spot specimens

Cholette F, Fabia R, Harris A, Ellis H, Cachero K, Schroeder L, et al

Cohort profile: Stop the Spread Ottawa (SSO)-a community-based prospective cohort study on antibody responses, antibody neutralisation efficiency and cellular immunity to SARS-CoV-2 infection and vaccination

Collins E, Galipeau Y, Arnold C, Bosveld C, Heiskanen A, Keeshan A, et al

Results of the Stop the Spread Ottawa (SSO) cohort study: a Canadian urban-based prospective evaluation of antibody responses and neutralisation efficiency to SARS-CoV-2 infection and vaccination

Keeshan A, Galipeau Y, Heiskanen A, Collins E, McCluskie PS, Arnold C, et al

Self-reported COVID-19 test results in Canada, January 2020 to March 2022

Statistics Canada

The effect of dose-interval on antibody response to mRNA COVID-19 vaccines: a prospective cohort study

Almeida ND, Schiller I, Ke D, Sakr E, Plesa M, Vanamala S, et al

Seropositivity and risk factors for SARS-CoV-2 infection in a South Asian community in Ontario: a cross-sectional analysis of a prospective cohort study

Anand SS, Arnold C, Bangdiwala SI, Bolotin S, Bowdish D, Chanchlani R, et al

Cohort profile: investigating SARS-CoV-2 infection and the health and psychosocial impact of the COVID-19 pandemic in the Canadian CHILD Cohort

Azeez R, Lotoski L, Dubeau A, Rodriguez N, Reyna ME, Freitas T, et al

Household transmission of SARS-CoV-2 from unvaccinated asymptomatic and symptomatic household members with confirmed SARS-CoV-2 infection: an antibody-surveillance study

Bhatt M, Plint AC, Tang K, Malley R, Huy AP, McGahern C, et al

Antibody Seronegativity in COVID-19 RT-PCR-Positive Children

Bhatt M, Zemek RL, Tang K, Malley R, Plint AC, Pham-Huy A, et al

Antibody neutralization capacity after coronavirus disease 2019 vaccination in people with HIV in Canada

Costiniuk CT, Singer J, Lee T, Galipeau Y, McCluskie PS, Arnold C, et al

COVID-19 vaccine immunogenicity in people with HIV

Costiniuk CT, Singer J, Lee T, Langlois MA, Arnold C, Galipeau Y, et al

Prevalence of SARS-CoV-2 infection among obstetric patients in Ottawa, Canada: a descriptive study

Fakhraei R, Erwin E, Alibhai KM, Murphy MSQ, Dingwall-Harvey ALJ, White RR, et al

Continuous false positive results by SARS-CoV-2 rapid antigen testing: a case report

Galipeau Y, Xavier A, Dyks A, Cooper C, Langlois MA

Booster doses of COVID-19 vaccine enhance neutralization efficiency against XBB.1.5

Sakr E, Almeida ND, Langlois MA, Dasgupta K, Mazer BD

Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study

Vinh DC, Gouin JP, Cruz-Santiago D, Canac-Marquis M, Bernier S, Bobeuf F, et al

Cross-sectional Characterization of SARS-CoV-2 Antibody Levels and Decay Rates Following Infection of Unvaccinated Elderly Individuals

Whelan M, Galipeau Y, White-Al Habeeb N, Konforte D, Abou El Hassan M, Booth RA, et al

Few Canadians had antibodies against SARS-CoV-2 in early 2021

Statistics Canada

Long-term symptoms in Canadian adults who tested positive for COVID-19 or suspected an infection, January 2020 to August 2022

Statistics Canada

Between April and August 2022, 98% of Canadians had antibodies against COVID-19 and 54% had antibodies from a previous infection

Statistics Canada

Correlates of Breakthrough SARS-CoV-2 Infections in People with HIV: Results from the CIHR CTN 328 Study

Costiniuk CT, Lee T, Singer J, Galipeau Y, Arnold C, Langlois MA, et al

Hybrid immunity after BNT162b2 Covid-19 vaccine administration in children aged 5 to 11 years

Tsampalieros A, Zemek R, Barrowman N, Langlois MA, Arnold C, McGahern C, et al

bottom of page